Boston Scientific Corporation (NYSE:BSX) went up by 0.71% from its latest closing price compared to the recent 1-year high of $46.28. The company’s stock price has collected -1.65% of loss in the last five trading sessions. Press Release reported on 01/07/22 that Boston Scientific to Present New Data on Advances in Chronic Pain Care at the 2022 North American Neuromodulation Society (NANS) Meeting
Is It Worth Investing in Boston Scientific Corporation (NYSE :BSX) Right Now?
Boston Scientific Corporation (NYSE:BSX) scored a price-to-earnings ratio above its average ratio, recording 55.22 x from its present earnings ratio. Plus, the 36-month beta value for BSX is at 0.88. Opinions of the stock are interesting as 20 analysts out of 29 who provided ratings for Boston Scientific Corporation declared the stock was a “buy,” while 4 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $51.52, which is $8.68 above the current price. BSX currently public float of 1.42B and currently shorts hold a 0.95% ratio of that float. Today, the average trading volume of BSX was 7.52M shares.
BSX’s Market Performance
BSX stocks went down by -1.65% for the week, with a monthly jump of 2.74% and a quarterly performance of 0.64%, while its annual performance rate touched 16.38%. The volatility ratio for the week stands at 2.36% while the volatility levels for the past 30 days are set at 2.18% for Boston Scientific Corporation. The simple moving average for the period of the last 20 days is 0.98% for BSX stocks with a simple moving average of -0.68% for the last 200 days.
Analysts’ Opinion of BSX
Many brokerage firms have already submitted their reports for BSX stocks, with RBC Capital Mkts repeating the rating for BSX by listing it as a “Outperform.” The predicted price for BSX in the upcoming period, according to RBC Capital Mkts is $51 based on the research report published on December 10th of the previous year 2021.
Barclays gave a rating of “Overweight” to BSX, setting the target price at $51 in the report published on May 25th of the previous year.
BSX Trading at 1.98% from the 50-Day Moving Average
After a stumble in the market that brought BSX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.37% of loss for the given period.
Volatility was left at 2.18%, however, over the last 30 days, the volatility rate increased by 2.36%, as shares surge +3.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.92% lower at present.
During the last 5 trading sessions, BSX fell by -1.65%, which changed the moving average for the period of 200-days by +10.96% in comparison to the 20-day moving average, which settled at $42.06. In addition, Boston Scientific Corporation saw -0.16% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BSX starting from Mirviss Jeffrey B., who sale 6,840 shares at the price of $43.54 back on Jan 04. After this action, Mirviss Jeffrey B. now owns 133,153 shares of Boston Scientific Corporation, valued at $297,806 using the latest closing price.
Pierce David A, the EVP Pres MedSurg of Boston Scientific Corporation, sale 6,161 shares at $43.54 during a trade that took place back on Jan 04, which means that Pierce David A is holding 0 shares at $268,230 based on the most recent closing price.
Stock Fundamentals for BSX
Current profitability levels for the company are sitting at:
- +6.06 for the present operating margin
- +56.25 for the gross margin
The net margin for Boston Scientific Corporation stands at -0.83. The total capital return value is set at 2.44, while invested capital returns managed to touch -0.34. Equity return is now at value 6.90, with 3.50 for asset returns.
Based on Boston Scientific Corporation (BSX), the company’s capital structure generated 62.73 points at debt to equity in total, while total debt to capital is 38.55. Total debt to assets is 31.24, with long-term debt to equity ratio resting at 62.18. Finally, the long-term debt to capital ratio is 38.21.
When we switch over and look at the enterprise to sales, we see a ratio of 5.90, with the company’s debt to enterprise value settled at 0.16. The receivables turnover for the company is 5.72 and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.82.